Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.

Langut Y, Talhami A, Mamidi S, Shir A, Zigler M, Joubran S, Sagalov A, Flashner-Abramson E, Edinger N, Klein S, Levitzki A.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13655-13660. doi: 10.1073/pnas.1714587115. Epub 2017 Dec 11.

PMID:
29229829
2.

S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock.

Shir A, Klein S, Sagiv-Barfi I, Geiger T, Zigler M, Langut Y, Edinger N, Levitzki A.

J Infect Dis. 2018 Jan 4;217(2):288-297. doi: 10.1093/infdis/jix576.

PMID:
29149330
3.

Trehalose supplementation reduces hepatic endoplasmic reticulum stress and inflammatory signaling in old mice.

Pagliassotti MJ, Estrada AL, Hudson WM, Wei Y, Wang D, Seals DR, Zigler ML, LaRocca TJ.

J Nutr Biochem. 2017 Jul;45:15-23. doi: 10.1016/j.jnutbio.2017.02.022. Epub 2017 Apr 6.

PMID:
28431320
4.

Voluntary aerobic exercise increases arterial resilience and mitochondrial health with aging in mice.

Gioscia-Ryan RA, Battson ML, Cuevas LM, Zigler MC, Sindler AL, Seals DR.

Aging (Albany NY). 2016 Nov 22;8(11):2897-2914. doi: 10.18632/aging.101099.

5.

Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways.

Lesniewski LA, Seals DR, Walker AE, Henson GD, Blimline MW, Trott DW, Bosshardt GC, LaRocca TJ, Lawson BR, Zigler MC, Donato AJ.

Aging Cell. 2017 Feb;16(1):17-26. doi: 10.1111/acel.12524. Epub 2016 Sep 22.

6.

Targeting polyIC to EGFR over-expressing cells using a dsRNA binding protein domain tethered to EGF.

Edinger N, Lebendiker M, Klein S, Zigler M, Langut Y, Levitzki A.

PLoS One. 2016 Sep 6;11(9):e0162321. doi: 10.1371/journal.pone.0162321. eCollection 2016.

7.

HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment.

Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, Lau J, Yu SF, Mizraji G, Globerson Levin A, Sliwkowski MX, Levitzki A.

Cancer Immunol Res. 2016 Aug;4(8):688-97. doi: 10.1158/2326-6066.CIR-15-0203. Epub 2016 May 30.

8.

Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery.

Joubran S, Zigler M, Pessah N, Klein S, Shir A, Edinger N, Sagalov A, Razvag Y, Reches M, Levitzki A.

Bioconjug Chem. 2014 Sep 17;25(9):1644-54. doi: 10.1021/bc500252a. Epub 2014 Aug 14.

PMID:
25121341
9.

Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice.

Gioscia-Ryan RA, LaRocca TJ, Sindler AL, Zigler MC, Murphy MP, Seals DR.

J Physiol. 2014 Jun 15;592(12):2549-61. doi: 10.1113/jphysiol.2013.268680. Epub 2014 Mar 24.

10.

Aging compounds western diet-associated large artery endothelial dysfunction in mice: prevention by voluntary aerobic exercise.

Lesniewski LA, Zigler ML, Durrant JR, Nowlan MJ, Folian BJ, Donato AJ, Seals DR.

Exp Gerontol. 2013 Nov;48(11):1218-25. doi: 10.1016/j.exger.2013.08.001. Epub 2013 Aug 13.

11.

Targeted cancer immunotherapy.

Zigler M, Shir A, Levitzki A.

Curr Opin Pharmacol. 2013 Aug;13(4):504-10. doi: 10.1016/j.coph.2013.04.003. Epub 2013 May 3. Review.

PMID:
23648271
12.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

13.

Curcumin ameliorates arterial dysfunction and oxidative stress with aging.

Fleenor BS, Sindler AL, Marvi NK, Howell KL, Zigler ML, Yoshizawa M, Seals DR.

Exp Gerontol. 2013 Feb;48(2):269-76. doi: 10.1016/j.exger.2012.10.008. Epub 2012 Nov 7.

14.

Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin.

Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, McConkey DJ, Shoshan E, Mobley AK, Song R, Raz A, Bar-Eli M.

Cancer Res. 2012 Nov 15;72(22):5757-66. doi: 10.1158/0008-5472.CAN-12-2424. Epub 2012 Sep 17.

15.

Sustained activation of AMPK ameliorates age-associated vascular endothelial dysfunction via a nitric oxide-independent mechanism.

Lesniewski LA, Zigler MC, Durrant JR, Donato AJ, Seals DR.

Mech Ageing Dev. 2012 May;133(5):368-71. doi: 10.1016/j.mad.2012.03.011. Epub 2012 Mar 28.

16.

Superoxide-lowering therapy with TEMPOL reverses arterial dysfunction with aging in mice.

Fleenor BS, Seals DR, Zigler ML, Sindler AL.

Aging Cell. 2012 Apr;11(2):269-76. doi: 10.1111/j.1474-9726.2011.00783.x. Epub 2012 Jan 19.

17.

PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

Zigler M, Kamiya T, Brantley EC, Villares GJ, Bar-Eli M.

Cancer Res. 2011 Nov 1;71(21):6561-6. doi: 10.1158/0008-5472.CAN-11-1432. Epub 2011 Oct 18. Review.

18.

A phase II study of gefitinib in patients with metastatic melanoma.

Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY.

Melanoma Res. 2011 Aug;21(4):357-63. doi: 10.1097/CMR.0b013e3283471073.

19.

Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression.

Zigler M, Villares GJ, Dobroff AS, Wang H, Huang L, Braeuer RR, Kamiya T, Melnikova VO, Song R, Friedman R, Alani RM, Bar-Eli M.

Cancer Res. 2011 May 15;71(10):3494-504. doi: 10.1158/0008-5472.CAN-10-3555. Epub 2011 Apr 5.

20.

The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.

Villares GJ, Zigler M, Bar-Eli M.

Oncotarget. 2011 Jan-Feb;2(1-2):8-17. Review.

21.

Nitrite supplementation reverses vascular endothelial dysfunction and large elastic artery stiffness with aging.

Sindler AL, Fleenor BS, Calvert JW, Marshall KD, Zigler ML, Lefer DJ, Seals DR.

Aging Cell. 2011 Jun;10(3):429-37. doi: 10.1111/j.1474-9726.2011.00679.x. Epub 2011 Mar 31.

22.

Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.

Villares GJ, Zigler M, Dobroff AS, Wang H, Song R, Melnikova VO, Huang L, Braeuer RR, Bar-Eli M.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):626-31. doi: 10.1073/pnas.1006886108. Epub 2010 Dec 27.

23.

Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Braeuer RR, Zigler M, Villares GJ, Dobroff AS, Bar-Eli M.

Semin Cancer Biol. 2011 Apr;21(2):83-8. doi: 10.1016/j.semcancer.2010.12.007. Epub 2010 Dec 13. Review.

24.

CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.

Melnikova VO, Dobroff AS, Zigler M, Villares GJ, Braeuer RR, Wang H, Huang L, Bar-Eli M.

PLoS One. 2010 Aug 27;5(8):e12452. doi: 10.1371/journal.pone.0012452.

25.

Cell adhesion: implication in tumor progression.

Zigler M, Dobroff AS, Bar-Eli M.

Minerva Med. 2010 Jun;101(3):149-62. Review.

PMID:
20562803
26.

Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, Petersson F, Price JE, Schroit A, Prieto VG, Hung MC, Bar-Eli M.

J Biol Chem. 2009 Oct 16;284(42):28845-55. doi: 10.1074/jbc.M109.042150. Epub 2009 Aug 24.

27.

Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.

Villares GJ, Dobroff AS, Wang H, Zigler M, Melnikova VO, Huang L, Bar-Eli M.

Cancer Res. 2009 Aug 15;69(16):6730-7. doi: 10.1158/0008-5472.CAN-09-0300.

28.

Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma.

Dobroff AS, Wang H, Melnikova VO, Villares GJ, Zigler M, Huang L, Bar-Eli M.

J Biol Chem. 2009 Sep 18;284(38):26194-206. doi: 10.1074/jbc.M109.019836. Epub 2009 Jul 24.

29.

Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.

Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli M.

Cancer Res. 2008 Nov 1;68(21):9078-86. doi: 10.1158/0008-5472.CAN-08-2397.

30.

A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans.

Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD.

Cancer Res. 2008 Oct 15;68(20):8419-28. doi: 10.1158/0008-5472.CAN-08-1242.

31.

Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape.

Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M.

Am J Clin Dermatol. 2008;9(5):307-11. Review.

PMID:
18717605
32.

Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.

Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, Zigler M, Wang H, Bar-Eli M, Kerbel RS, Fidler IJ.

Neoplasia. 2008 May;10(5):489-500.

33.

Targeting EGFR in bladder cancer.

Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D, Bar-Eli M.

World J Urol. 2007 Dec;25(6):573-9. Epub 2007 Aug 10. Retraction in: World J Urol. 2012 Oct;30(5):723.

PMID:
17690890
34.

S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells.

Zaman K, Carraro S, Doherty J, Henderson EM, Lendermon E, Liu L, Verghese G, Zigler M, Ross M, Park E, Palmer LA, Doctor A, Stamler JS, Gaston B.

Mol Pharmacol. 2006 Oct;70(4):1435-42. Epub 2006 Jul 20.

35.

Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors.

Foss FW Jr, Clemens JJ, Davis MD, Snyder AH, Zigler MA, Lynch KR, Macdonald TL.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4470-4.

PMID:
16125386
36.

Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720.

Kharel Y, Lee S, Snyder AH, Sheasley-O'neill SL, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, Tung KS, Engelhard VH, Macdonald TL, Pearson-White S, Lynch KR.

J Biol Chem. 2005 Nov 4;280(44):36865-72. Epub 2005 Aug 10.

37.

6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency.

Chordia MD, Zigler M, Murphree LJ, Figler H, Macdonald TL, Olsson RA, Linden J.

J Med Chem. 2005 Aug 11;48(16):5131-9.

PMID:
16078833
39.

Thin-layer chromatographic method for estimation of chlorophenols.

Zigler MG, Phillips WF.

Environ Sci Technol. 1967 Jan;1(1):65-7. doi: 10.1021/es60001a004. No abstract available.

PMID:
22148340
40.
41.

Variability of dark adaptation.

WOLF E, ZIGLER MJ, COWEN-SOLOMONS HB.

J Opt Soc Am. 1960 Oct;50:961-5. No abstract available.

PMID:
13786258
42.

Some relationships of glare and target perception.

WOLF E, ZIGLER MJ.

WADC Tech Rep United States Air Force Wright Air Dev Cent Day Ohio. 1959 Sep;59-394:1-29. No abstract available.

PMID:
13845634
43.

Uniocular and binocular scotopic responsiveness of the peripheral retina.

WOLF E, ZIGLER MJ.

J Opt Soc Am. 1959 Apr;49(4):394-8. No abstract available.

PMID:
13631566
44.

Uniocular and binocular scotopic parafoveal sensitivity.

ZIGLER MJ, WOLF E.

Am J Psychol. 1958 Mar;71(1):186-98. No abstract available.

PMID:
13521029
45.

Course of dark adaptation under various conditions of pre-exposure and testing.

WOLF E, ZIGLER MJ.

J Opt Soc Am. 1955 Sep;45(9):696-702. No abstract available.

PMID:
13252486
46.

Location of the break in the dark adaptation curve in relation to pre-exposure brightness and pre-exposure time.

WOLF E, ZIGLER MJ.

J Opt Soc Am. 1954 Nov;44(11):875-9. No abstract available.

PMID:
13212525
47.

Post-contractional fatigue; change in magnitude of involuntary behavior as a function of successive tensive stimulations.

ZIGLER MJ, MARTIN B, et al.

J Comp Physiol Psychol. 1948 Apr;41(2):124-36. No abstract available.

PMID:
18872675

Supplemental Content

Loading ...
Support Center